Duke Street Bio
Develops cancer therapies targeting DNA damage repair deficiencies for patients with cancer
Highlights
- New on EvolcAdded 2026-10-31
About Duke Street Bio
Duke Street Bio develops molecules targeting DNA damage repair (DDR) deficiencies in cancer, using a precision medicine approach and seeking to harness anti-tumour immune responses.
The company is based in London and was founded in 2020. Its team includes management and scientific advisers with drug-development and oncology experience.
Product: Drug-development programs focused on molecules targeting DNA damage repair deficiencies in cancer.
Jobs at Duke Street Bio
No open positions listed right now.
Leadership
- Alan Wise · Chief Executive OfficerSource: company website
- Barry McGuinness · Chief Operating OfficerSource: company website
More biotech & pharma companies
Elasmogen
Biopharma developing ELN28, a dual-acting TNFα and JAK inhibitor conjugate for hidradenitis suppurativa patientsNew on EvolcEleventx
Extended-release RNA medicines for chronic disease, starting in cardiometabolic, developed with pharma partnersEnara Bio
Cancer immunotherapies for patients with solid tumors, developed using dark-antigen discovery and T-cell engager platformsNew on EvolcEnsocell
AI-driven discovery of precision therapies for fibrotic and autoimmune diseases using human biological dataNew on EvolcEnterobiotix
Clinical-stage microbiome therapeutics developing the oral drug EBX-102-02 for irritable bowel syndrome and related gut and liver diseasesNew on EvolcEnterprise Therapeutics
Develops investigational medicines for people with cystic fibrosis and other respiratory diseasesNew on Evolc
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Apache
- Google Analytics 4
- Google reCAPTCHA
- WooCommerce
- WordPress
- jQuery